Supernus Corp (SUPN): Koefisien rega marang pendapatan
Stable distribution channels eliminate supply disruptions for neuropreparations for Supernus Pharmaceuticals (SUPN). The estimated price-to-sales ratio visualizes the market valuation of assets, where the 2.70 level represents the current value. Market share protection is based on unique substance-release formulas. High scalability is ensured through subsequent global commercialization of products following successful clinical trials.
Rincian analitis perusahaan Supernus Corp (SUPN)
- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian nilai buku perusahaan:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Supernus Pharmaceuticals|SUPN - Utang jangka dawa marang modal|Utang jangka cendhak marang modal supernus.com|SUPN - Utang perusahaan|Rasio utang marang aset resik Supernus|SUPN - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Supernus|Rasio cepet supernus.com
- informasi bathi lan kelipatan valuasi:
SUPN - Bathi resik|Bathi mangsa ngarep Supernus Pharmaceuticals|SUPN - Pangali P/E|Rasio prakiraan rega marang bathi Supernus Pharmaceuticals|SUPN - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Supernus Pharmaceuticals|SUPN - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Supernus|SUPN - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan supernus.com|SUPN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Supernus Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Supernus Pharmaceuticals, Inc., SUPN
For Supernus Pharmaceuticals (SUPN), whose revenues depend on long-term contracts with healthcare systems for the supply of CNS therapy drugs, the P/S levels on this chart reflect the market value of one dollar of revenue. The ratio of market capitalization to sales allows for an assessment of the premium paid for the business, where low values create a defensive buffer and high values increase the risk of a correction during a trend reversal.
Pesaing Supernus Pharmaceuticals
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|CPRX (Catalyst Pharmaceuticals Inc) - Multiplikator P/S|DNLI: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan harmonybiosciences.com (HRMY)|Biohaven - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AMLX (amylyx.com)|Trevi Pharma (TRVI) - Rega marang dodolan|Praxis Corp - Multiplikator P/S|Anavex Corp (AVXL) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|Prothena Biosciences - Rasio kapitalisasi pasar marang pendapatan|ALEC (alector.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANNX (Annexon Biosciences)|Rasio rega marang pendapatan Omeros Corporation (OMER)|Neurogene Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan AC Immune S.A. ACIU|Koefisien rega marang pendapatan Voyager Therapeutics (VYGR)|Neumora - Multiplikator P/S|Rasio rega marang dodolan SCLX|Tevogen Bio Inc. (TVGN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan ACOG|CGTX (cogrx.com) - Multiplikator P/S|Kapitalisasi marang pendapatan inhibikase.com (IKT)|Rasio rega marang pendapatan Cassava Sciences Inc (SAVA)|Koefisien rega marang pendapatan Assertio|Multiplikator P/S COYA (Coya Therapeutics, Inc.)|Kapitalisasi marang volume dodolan VTGN (VistaGen Therapeutics Inc)|OVID: Kapitalisasi marang pendapatan|ABOS: Rasio rega marang pendapatan|CervoMed (CRVO) - Rasio rega marang pendapatan|Rega marang dodolan Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences, Inc.)|Multiplikator P/S relmada.com (RLMD)|Rasio rega marang pendapatan Annovis Bio Corp ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
